ClinicalTrials.gov
public full text
Public Domain
OM336 in Seropositive Autoimmune Diseases
An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of OM336 in adult participants with seropositive autoimmune diseases. OM336 is administered subcutaneously in ascending dose cohorts.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Guideline Approach to Therapy Step-down Utilising Flutiform Change and Step-down#886558
- A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis#885747
- BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab#889312
- Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1#892619
- Immunological Reset to Enable Access to Hla-compatible Kidney Transplantation in Highly Sensitized Patients (RESET)#1102981
Record · ID 801826
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive